Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
复制标题
DOI：
10.1016/j.cld.2017.08.013
复制
发表时间：
2018-02-01
影响因子：
5.1
通讯作者：
Chalasani, Naga
中科院分区：
文献类型：
--
作者：
Gawrieh, Samer;Chalasani, Naga
本文讨论了已完成的II期随机临床试验，其中高质量的已发表结果表明化合物对非酒精性脂肪性肝炎组织学（奥贝胆酸，elafibranor和利拉鲁肽）的影响。作者还审查了cenicriviroc和selonsertib的现有初步数据，有或没有simtuzumab的II期研究。最后，作者简要讨论了已测试但未达到组织学改善的主要终点并出现在高质量已发表文章中的化合物（半胱胺酒石酸氢盐和长链多不饱和脂肪酸）。
This article discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).